Assessment of intravitreal ocriplasmin treatment for vitreomacular traction in clinical practice

[1] Duker JS(2013)The international Vitreomacular traction study group classification of vitreomacular adhesion, traction, and macular hole Ophthalmology 120 2611-2619

[2] Kaiser PK(2004)Posterior vitreous detachment induced by microplasmin Invest Ophthalmol Vis Sci 45 641-647

[3] Binder S(2009)Microplasmin: ex vivo characterization of its activity in porcine vitreous Invest Ophthalmol Vis Sci 50 814-819

[4] Gandorfer A(2009)Microplasmin intravitreal administration in patients with vitreomacular traction scheduled for vitrectomy: the MIVI I trial Ophthalmology 116 1349-1355

[5] Rohleder M(2012)MIVI-TRUST study group. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes N Engl J Med 367 606-615

[6] Sethi C(2015)Efficacy of intravitreal ocriplasmin for treatment of vitreomacular adhesion. Subgroup analyses from two randomized trials Ophthalmology 122 117-122

[7] de Smet MD(2015)MIVI-TRUST study group. Association between anatomical resolution and functional outcomes in the MIVI-Trust studies using ocriplasmin to treat symptomatic vitreomacular adhesion/vitreomacular traction, including when associated with macular hole Retina 35 1151-1157

[8] Valmaggia C(2013)Initial outcomes following intravitreal ocriplasmin for treatment of symptomatic vitreomacular adhesion Ophthalmic Surg Lasers Imaging Retina 44 334-343

[9] Zarranz-Ventura J(2014)Anatomical and visual outcomes following ocriplasmin treatment for symptomatic vitreomacular traction syndrome Br J Ophthalmol 98 356-360

[10] Willekens B(2015)Efficacy of intravitreal ocriplasmin on vitreomacular traction and full-thickness macular holes Am J Ophthalmol 159 861.e2–867.e2-2247

[1] Duker JS(2013)The international Vitreomacular traction study group classification of vitreomacular adhesion, traction, and macular hole Ophthalmology 120 2611-2619

[2] Kaiser PK(2004)Posterior vitreous detachment induced by microplasmin Invest Ophthalmol Vis Sci 45 641-647

[3] Binder S(2009)Microplasmin: ex vivo characterization of its activity in porcine vitreous Invest Ophthalmol Vis Sci 50 814-819

[4] Gandorfer A(2009)Microplasmin intravitreal administration in patients with vitreomacular traction scheduled for vitrectomy: the MIVI I trial Ophthalmology 116 1349-1355

[5] Rohleder M(2012)MIVI-TRUST study group. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes N Engl J Med 367 606-615

[6] Sethi C(2015)Efficacy of intravitreal ocriplasmin for treatment of vitreomacular adhesion. Subgroup analyses from two randomized trials Ophthalmology 122 117-122

[7] de Smet MD(2015)MIVI-TRUST study group. Association between anatomical resolution and functional outcomes in the MIVI-Trust studies using ocriplasmin to treat symptomatic vitreomacular adhesion/vitreomacular traction, including when associated with macular hole Retina 35 1151-1157

[8] Valmaggia C(2013)Initial outcomes following intravitreal ocriplasmin for treatment of symptomatic vitreomacular adhesion Ophthalmic Surg Lasers Imaging Retina 44 334-343

[9] Zarranz-Ventura J(2014)Anatomical and visual outcomes following ocriplasmin treatment for symptomatic vitreomacular traction syndrome Br J Ophthalmol 98 356-360

[10] Willekens B(2015)Efficacy of intravitreal ocriplasmin on vitreomacular traction and full-thickness macular holes Am J Ophthalmol 159 861.e2–867.e2-2247